

Rhodium(III)-catalyzed *ortho*-C–H amidation of 2-arylindazoles with dioxazolone as an amidating reagent

Payel Ghosh, Sadhanendu Samanta and Alakananda Hajra*

Department of Chemistry, Visva-Bharati (A Central University), Santiniketan 731235, India;

Tel./Fax: +913463 261526; E-mail: alakananda.hajra@visva-bharati.ac.in

Table of Contents

Content	Page no.
1. General Information.....	S2
2. Typical experimental procedure for the compound 3aa	S2-S3
3. Mechanistic investigations.....	S3-S5
4. Characterization data for the synthesized products.....	S5-S16
5. References.....	S16
6. NMR spectra for the synthesized products.....	S18-S71

1. General Information:

All reagents were purchased from commercial sources and used without further purification. ^1H NMR spectra were determined on 400 MHz spectrometer as solutions in CDCl_3 . Chemical shifts were expressed in parts per million (δ) and the signals were reported as s (singlet), br s (broad singlet), d (doublet), dd (doublet of doublet), t (triplet), q (quartet), m (multiplet), and coupling constants (J) were given in Hz. $^{13}\text{C}\{^1\text{H}\}$ NMR spectra were recorded at 100 MHz in CDCl_3 solution. Chemical shifts as internal standard were referenced to CDCl_3 ($\delta = 7.26$ for ^1H and $\delta = 77.16$ for $^{13}\text{C}\{^1\text{H}\}$ NMR) as internal standard. TLC was done on silica gel coated glass slide. All solvents were dried and distilled before use. Commercially available solvents were freshly distilled before the reaction. All reactions involving moisture sensitive reactants were executed using oven dried glassware. All the 2*H*-indazoles and dioxazolone derivatives were prepared by the reported method.^{1,2}


2. Typical experimental procedure for the compound *N*-(2-(2*H*-indazol-2-yl)phenyl)acetamide (3aa):

A mixture of 2-phenyl-2*H*-indazole (**1a**) (0.2 mmol, 38.8 mg), $[\text{Cp}^*\text{RhCl}_2]_2$ (3 mol%, 3.7 mg), AgSbF_6 (20 mol%, 13.7 mg) and KPF_6 (40 mol%, 14.7 mg) was taken in an oven dried screw-capped reaction tube. Then 1,2-DCE (2 mL) was added to the mixture and stirred for 5 min at room temperature under open atmosphere. After that, 3-methyl-1,4,2-dioxazol-5-one (**2a**) (0.3 mmol, 30 mg) was added, and the resultant mixture was stirred at 110 °C for 3 h. After completion of the reaction (TLC), the reaction was cooled to room temperature and extracted with dichloromethane. The organic phase was dried over anhydrous Na_2SO_4 . The crude residue was obtained after evaporating the solvent in vacuum and was purified by column

chromatography on silica gel using a mixture of petroleum ether and ethyl acetate (83:17) as an eluting solvent to afford the pure product **3aa** (38 mg, 76%) as a white solid.


3. Mechanistic investigations:

3.1. Preparation of 2-(4-methylphenyl-2,6-d₂)-2*H*-indazole-3-d (1b-d₃):¹




A mixture of 2-(*p*-tolyl)-2*H*-indazole (0.2 mmol, 41 mg) (**1b**), [Cp*RhCl₂]₂ (3 mol%, 3.7 mg), AgSbF₆ (20 mol%, 13.7 mg), and KPF₆ (40 mol%, 14.7 mg) was taken in an oven dried screw-capped reaction tube. Then 1,2-DCE (2 mL) was added to the mixture and stirred for 5 min at room temperature under open atmosphere. After that, D₂O (1 mL) was added, and the resultant mixture was stirred at 110 °C for 3 h. Then, the reaction was cooled to room temperature and extracted with dichloromethane. The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate (75:25) as an eluting solvent to afford the pure product **1b-d₃** as a white solid. The deuterium incorporation was determined using 400 MHz ¹H NMR as 100%.

3.2. Intermolecular kinetic isotope effect study:²



3-Methyl-1,4,2-dioxazol-5-one (**2a**) (0.3 mmol, 30 mg) was reacted with 2-(*p*-tolyl)-2*H*-indazole (**1b**) (0.1 mmol, 20.8 mg) and 2-(4-methylphenyl-2,6-*d*₂)-2*H*-indazole-3-*d* (**1b-d**₃) (0.1 mmol, 21.1 mg) for 10 min under standard reaction condition. The resulting solution was then diluted with dichloromethane (3 x 10 mL) and washed with brine (2 x 5 mL) and water (5 mL). The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and was purified by column chromatography on silica gel using a mixture of petroleum ether and ethyl acetate (80:20) as an eluting solvent to afford **3ba** and a mixture of unreacted **1b** and **1b-d**₃ as a white solid. The intermolecular *K_H/K_D* was found to be 4.26 after 10 min at 19% conversion, based on 400 MHz ¹H NMR of the product **3ba** and **3ba-d**₂.


3.3. Independent kinetic isotope effect study:²




In a set of two experiments: in first set, 3-methyl-1,4,2-dioxazol-5-one (**2a**) (0.15 mmol, 15 mg) was reacted with 2-(*p*-tolyl)-2*H*-indazole (**1b**) (0.1 mmol, 20.8 mg) under standard reaction conditions. Whereas in another set, 2-(4-methylphenyl-2,6-*d*₂)-2*H*-indazole-3-*d* (**1b-d**₃) (0.1 mmol, 21.1 mg) was used instead of **1b** in the reaction with 3-methyl-1,4,2-dioxazol-5-one (**2a**) (0.15 mmol, 15 mg) under the standard reaction conditions. The two reactions were allowed to stir at 110 °C for 10 min. The resulting solution was then diluted with dichloromethane (3 x 10 mL) and washed with brine (2 x 5 mL) and water (5 mL). The organic phase was dried over anhydrous Na₂SO₄. The crude residue was obtained after evaporating the solvent in vacuum and

was purified by column chromatography on silica gel using a mixture petroleum ether and ethyl acetate (80:20) as an eluting solvent to afford **3ba**. The yield of **3ba** was obtained as 29% and 7% yields, respectively. The KIE value of 4.14 was determined by the ratio of obtained yield of **3ba** ($KIE = 29\%/7\%/100\% = 4.14$).


3. Characterization data for the synthesized products:




2-(4-Chlorophenyl)-5-fluoro-2H-indazole (1n): Yellow solid (86%, 634.75 mg, 3.0 mmol); $R_f = 0.55$ (PE:EA = 95:05); M.p. 98-99 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.43 (s, 1H), 8.04-8.03 (m, 1H), 7.86-7.83 (m, 2H), 7.56-7.52 (m, 1H), 7.48-7.46 (m, 1H), 7.36-7.33 (m, 1H), 7.26-7.21 (m, 1H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 158.9 (d, $J_{\text{C}-\text{F}} = 240.0$ Hz), 147.4, 141.3, 135.5, 130.7, 128.1, 122.2 (d, $J_{\text{C}-\text{F}} = 12.0$ Hz), 121.2, 120.5 (d, $J_{\text{C}-\text{F}} = 9.0$ Hz), 120.2 (d, $J_{\text{C}-\text{F}} = 10.0$ Hz), 119.2, 118.5 (d, $J_{\text{C}-\text{F}} = 29.0$ Hz), 102.8 (d, $J_{\text{C}-\text{F}} = 23.0$ Hz); Anal. Calcd for $\text{C}_{13}\text{H}_8\text{ClFN}_2$: C, 63.30; H, 3.27; N, 11.36%; Found: C, 63.45; H, 3.33; N, 11.25%.




N-(2-(2H-Indazol-2-yl)phenyl)acetamide (3aa): White solid (76%, 38.1 mg); $R_f = 0.50$ (PE:EA = 83:17); M.p. 180-181 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.61 (s, 1H), 8.54 (d, $J = 8.4$ Hz, 1H), 8.28 (s, 1H), 7.67 (t, $J = 9.2$ Hz, 2H), 7.46-7.37 (m, 3H), 7.18 (q, $J = 8.4$ Hz, 2H), 2.12 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.6, 149.8, 132.2, 129.2, 129.1, 127.6, 124.3, 124.0, 123.6, 123.0, 122.8, 121.9, 120.6, 117.2, 25.1; HRMS (ESI-TOF) m/z : $[\text{M} + \text{H}]^+$ Calcd for $[\text{C}_{15}\text{H}_{14}\text{N}_3\text{O}]^+$: 252.1131; found: 252.1135.




N-(2-(2H-Indazol-2-yl)-5-methylphenyl)acetamide (3ba): White solid (90%, 47.7 mg); R_f = 0.5 (PE:EA = 82:18); M.p. 183-184 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.52 (s, 1H), 8.36 (s, 1H), 8.26 (s, 1H), 7.76 (t, J = 8.4 Hz, 2H), 7.40-7.33 (m, 2H), 7.19-7.15 (m, 1H), 7.01 (d, J = 9.6 Hz, 1H), 2.43 (s, 3H), 2.11 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.6, 149.7, 139.6, 131.9, 127.5, 126.9, 124.8, 124.2, 123.4, 123.3, 122.7, 121.9, 120.6, 117.3, 25.2, 21.6; Anal. Calcd for C₁₆H₁₅N₃O: C, 72.43; H, 5.70; N, 15.84%; Found: C, 72.65; H, 5.65; N, 15.90%.




N-(2-(2H-Indazol-2-yl)-5-methoxyphenyl)acetamide (3ca): White solid (81%, 45.5 mg); R_f = 0.45 (PE:EA = 80:20); M.p. 188-189 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.56 (s, 1H), 8.22 (s, 2H), 7.75 (t, J = 8.0 Hz, 2H), 7.40-7.35 (m, 2H), 7.18-7.14 (m, 1H), 6.73 (dd, J = 8.8 Hz, 2.8 Hz, 1H), 3.88 (s, 3H), 2.12 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.8, 160.1, 149.7, 133.5, 127.4, 124.6, 124.1, 122.7, 122.5, 121.9, 120.5, 117.2, 110.3, 107.1, 55.7, 25.3; Anal. Calcd for C₁₆H₁₅N₃O₂: C, 68.31; H, 5.37; N, 14.94%; Found: C, 68.12; H, 5.33; N, 15.03%.




N-(5-Fluoro-2-(2H-indazol-2-yl)phenyl)acetamide (3da): White solid (85%, 45.7 mg); $R_f = 0.55$ (PE:EA = 85:15); M.p. 179-180 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.66 (s, 1H), 8.42 (dd, $J = 11.2$ Hz, 2.8 Hz, 1H), 8.25 (s, 1H), 7.78-7.75 (m, 2H), 7.44-7.38 (m, 2H), 7.21-7.17 (m, 1H), 6.92-6.87 (m, 1H), 2.13 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 162.5 (d, $J_{\text{C}-\text{F}} = 246.0$ Hz), 149.9, 134.0 (d, $J_{\text{C}-\text{F}} = 11.0$ Hz), 127.8, 125.2, 124.9 (d, $J_{\text{C}-\text{F}} = 10.0$ Hz), 124.4, 123.0, 122.0, 120.6, 117.3, 110.6 (d, $J_{\text{C}-\text{F}} = 23.0$ Hz), 109.9 (d, $J_{\text{C}-\text{F}} = 29.0$ Hz), 25.2; Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{FN}_3\text{O}$: C, 66.91; H, 4.49; N, 15.60%; Found: C, 67.08; H, 4.56; N, 15.49%.




N-(5-Chloro-2-(2H-indazol-2-yl)phenyl)acetamide (3ea): White solid (88%, 50.2 mg); $R_f = 0.5$ (PE:EA = 84:16); M.p. 192-193 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.75 (s, 1H), 8.67 (s, 1H), 8.27 (s, 1H), 7.77-7.74 (m, 2H), 7.42-7.38 (m, 2H), 7.20-7.16 (m, 2H), 2.14 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 149.9, 135.0, 133.3, 127.9, 127.3, 124.4, 124.3, 123.9, 123.1, 122.7, 122.0, 120.6, 117.3, 25.2; Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{ClN}_3\text{O}$: C, 63.05; H, 4.23; N, 14.71%; Found: C, 62.87; H, 4.17; N, 14.79%.




N-(4-Chloro-2-(2H-indazol-2-yl)phenyl)acetamide (3fa): White solid (91%, 52.0 mg); $R_f = 0.50$ (PE:EA = 84:16); M.p. 190-191 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.68 (s, 1H), 8.54 (d, $J = 8.8$ Hz, 1H), 8.30 (s, 1H), 7.77-7.74 (m, 2H), 7.48 (d, $J = 2.4$ Hz, 1H), 7.42-7.38 (m, 2H), 7.21-7.17 (m, 1H), 2.13 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 150.0, 131.0, 129.6, 129.0, 128.8, 128.0, 124.3, 124.1, 123.5, 123.2, 122.0, 120.7, 117.3, 25.2; Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{ClN}_3\text{O}$: C, 63.05; H, 4.23; N, 14.71%; Found: C, 63.20; H, 4.27; N, 14.61%.




N-(4-Chloro-5-fluoro-2-(2H-indazol-2-yl)phenyl)acetamide (3ga): White solid (82%, 49.8 mg); $R_f = 0.55$ (PE:EA = 85:15); M.p. 194–195 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.78 (s, 1H), 8.56 (d, $J = 11.2$ Hz, 1H), 8.26 (m, 1H), 7.76–7.73 (m, 2H), 7.51 (d, $J = 6.8$ Hz, 1H), 7.43–7.38 (m, 1H), 7.21–7.17 (m, 1H), 2.14 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 157.6 (d, $J_{\text{C}-\text{F}} = 248.0$ Hz), 149.9, 132.4 (d, $J_{\text{C}-\text{F}} = 11.0$ Hz), 128.1, 125.3 (d, $J_{\text{C}-\text{F}} = 3.0$ Hz), 124.9, 124.3, 123.3, 122.0, 120.6, 117.2, 115.2 (d, $J_{\text{C}-\text{F}} = 20.0$ Hz), 110.7 (d, $J_{\text{C}-\text{F}} = 28.0$ Hz), 25.2; Anal. Calcd for $\text{C}_{15}\text{H}_{11}\text{ClFN}_3\text{O}$: C, 59.32; H, 3.65; N, 13.84%; Found: C, 59.11; H, 3.70; N, 13.89%.




N-(5-Bromo-2-(2H-indazol-2-yl)phenyl)acetamide (3ha): White solid (89%, 58.7 mg); $R_f = 0.5$ (PE:EA = 82:18); M.p. 187–188 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.78 (s, 1H), 8.81 (s, 1H), 8.27 (s, 1H), 7.77–7.73 (m, 2H), 7.42–7.38 (m, 1H), 7.31 (s, 2H), 7.20–7.16 (m, 1H), 2.13 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 149.9, 133.4, 127.9, 127.7, 126.9, 125.5, 124.6, 124.2, 123.2, 122.9, 122.0, 120.6, 117.3, 25.3; Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{BrN}_3\text{O}$: C, 54.56; H, 3.66; N, 12.73%; Found: C, 54.42; H, 3.61; N, 12.66%.



N-(4-Bromo-2-(2H-indazol-2-yl)phenyl)acetamide (3ia): White solid (79%, 52.1 mg); $R_f = 0.55$ (PE:EA = 80:20); M.p. 184-185 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.68 (s, 1H), 8.49 (d, $J = 9.2$ Hz, 1H), 8.30 (s, 1H), 7.77-7.74 (m, 2H), 7.63 (d, $J = 2.4$ Hz, 1H), 7.53 (dd, $J = 9.2$ Hz, 2.4 Hz, 1H) 7.43-7.39 (m, 1H), 7.21-7.17 (m, 1H), 2.13 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 150.0, 132.0, 131.5, 129.8, 128.0, 127.0, 126.3, 124.3, 123.2, 122.0, 120.7, 117.3, 115.9, 25.2; Anal. Calcd for $\text{C}_{15}\text{H}_{12}\text{BrN}_3\text{O}$: C, 54.56; H, 3.66; N, 12.73%; Found: C, 54.75; H, 3.69; N, 12.81%.




Ethyl 3-acetamido-4-(2H-indazol-2-yl)benzoate (3ja): White solid (87%, 56.2 mg); $R_f = 0.45$ (PE:EA = 75:25); M.p. 198-199 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.88 (s, 1H), 9.19 (s, 1H), 8.36 (s, 1H), 7.91-7.89 (m, 1H), 7.78-7.75 (m, 2H), 7.55 (d, $J = 8.4$ Hz, 1H), 7.43-7.39 (m, 1H), 7.21-7.17 (m, 1H), 4.41 (q, $J = 7.6$ Hz, 2H), 2.16 (s, 3H), 1.42 (t, $J = 7.2$ Hz, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.7, 165.6, 150.0, 132.2, 131.9, 131.1, 128.1, 125.3, 124.47, 124.42, 123.3, 122.1, 120.7, 117.4, 61.5, 25.2, 14.4; HRMS (ESI-TOF) m/z : [M + H]⁺ Calcd for $[\text{C}_{18}\text{H}_{18}\text{N}_3\text{O}_3]^{+}$: 324.1343; found: 324.1342.




N-(2-(5-Methoxy-2H-indazol-2-yl)-5-methylphenyl)acetamide (3ka): White solid (83%, 49.0 mg); $R_f = 0.45$ (PE:EA = 77:23); M.p. 196-197 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.47 (s, 1H), 8.35 (s, 1H), 8.10 (s, 1H), 7.65 (d, $J = 9.2$ Hz, 1H), 7.32 (d, $J = 8.4$ Hz, 1H), 7.09 (dd, $J = 9.6$ Hz, 2.4 Hz, 1H), 7.00-6.98 (m, 1H), 6.93 (d, $J = 2.0$ Hz, 1H), 3.86 (s, 3H), 2.42 (s, 3H), 2.11 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 168.6, 155.8, 146.6, 139.3, 131.9, 127.0, 124.7, 123.3, 123.0, 122.8, 122.6, 122.0, 118.6, 96.5,


55.5, 25.2, 21.6; Anal. Calcd for C₁₇H₁₇N₃O₂: C, 69.14; H, 5.80; N, 14.23%; Found: C, 68.98; H, 5.73; N, 14.18%.




N-(5-Methoxy-2-(5-methoxy-2H-indazol-2-yl)phenyl)acetamide (3la): White solid (84%, 52.3 mg); R_f = 0.5 (PE:EA = 75:25); M.p. 201-202 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.51 (s, 1H), 8.20 (s, 1H), 8.05 (s, 1H), 7.64 (d, J = 9.2 Hz, 1H), 7.31 (d, J = 8.4 Hz, 1H), 7.07 (dd, J = 9.6 Hz, 2.4 Hz, 1H), 6.92 (s, 1H), 6.71-6.68 (m, 1H), 3.86 (s, 3H), 3.85 (s, 3H), 2.11 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.7, 159.8, 155.7, 146.5, 133.4, 124.4, 123.0, 122.6, 122.4, 122.0, 118.5, 110.1, 107.0, 96.5, 55.7, 55.5, 25.2; Anal. Calcd for C₁₇H₁₇N₃O₃: C, 65.58; H, 5.50; N, 13.50%; Found: C, 65.45; H, 5.53; N, 13.39%.




N-(2-(5-Fluoro-2H-indazol-2-yl)-5-methylphenyl)acetamide (3ma): White solid (78%, 44.1 mg); R_f = 0.55 (PE:EA = 84:16); M.p. 168-169 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.36 (s, 1H), 8.33 (s, 1H), 8.20 (s, 1H), 7.72 (q, J = 4.8 Hz, 1H), 7.32-7.29 (m, 2H), 7.20-7.14 (m, 1H), 7.00-6.98 (m, 1H), 2.41 (s, 3H), 2.10 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.6, 158.8, (d, J_{C-F} = 241.0 Hz), 147.0, 139.7, 131.8, 126.8, 124.8, 124.2 (d, J_{C-F} = 8.0 Hz), 123.4, 121.3, 121.2, 119.2 (d, J_{C-F} = 9.0 Hz), 119.1 (d, J_{C-F} = 29.0 Hz), 102.9 (d, J_{C-F} = 25.0 Hz), 25.1, 21.5; Anal. Calcd for C₁₆H₁₄FN₃O: C, 67.83; H, 4.98; N, 14.83%; Found: C, 67.98; H, 4.92; N, 14.93%.




N-(4-Chloro-2-(5-fluoro-2H-indazol-2-yl)phenyl)acetamide (3na): White solid (92%, 55.8 mg); R_f = 0.55 (PE:EA = 85:15); M.p. 205-206 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.50 (s, 1H), 8.51 (d, J = 8.8 Hz, 1H), 8.25 (s, 1H), 7.73 (q, J = 4.8 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 7.37 (dd, J = 9.2 Hz, 2.4 Hz, 1H), 7.31 (dd, J = 8.8 Hz, 2.4 Hz, 1H), 7.22-7.17 (m, 1H), 2.12 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.6, 159.0 (d, J_{C-F} = 240.0 Hz), 147.3, 130.8, 129.3 (d, J_{C-F} = 31.0 Hz), 128.8, 124.3 (d, J_{C-F} = 9.0 Hz), 124.2, 123.4, 121.4 (d, J_{C-F} = 12.0 Hz), 119.9, 119.6, 119.4 (d, J_{C-F} = 10.0 Hz), 103.0 (d, J_{C-F} = 25.0 Hz), 25.1; Anal. Calcd for C₁₅H₁₁ClFN₃O: C, 59.32; H, 3.65; N, 13.84%; Found: C, 59.15; H, 3.58; N, 13.72%.




N-(2-(5-Chloro-2H-indazol-2-yl)-5-methylphenyl)acetamide (3oa): White solid (86%, 51.5 mg); R_f = 0.50 (PE:EA = 85:15); M.p. 192-193 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.31 (s, 1H), 8.33 (s, 1H), 8.20 (s, 1H), 7.72-7.69 (m, 2H), 7.34-7.30 (m, 2H), 7.01 (d, J = 8.0 Hz, 1H), 2.43 (s, 3H), 2.11 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.6, 148.0, 140.0, 131.9, 128.9, 128.5, 126.7, 124.9, 123.8, 123.57, 123.52, 122.3, 119.2, 118.8, 25.2, 21.6; HRMS (ESI-TOF) m/z: [M + H]⁺ Calcd for C₁₆H₁₅ClN₃O: 300.0898; found: 300.0905.




N-(2-(5-Chloro-2H-indazol-2-yl)-5-methoxyphenyl)acetamide (3pa): White solid (89%, 56.2 mg); R_f = 0.5 (PE:EA = 80:20); M.p. 198-199 °C; ¹H NMR (400 MHz, CDCl₃): δ 10.36 (s, 1H), 8.20-8.17 (m, 2H), 7.72-7.68 (m, 2H), 7.36-7.30 (m, 2H), 6.74-6.72 (m, 1H), 3.87 (s, 3H), 2.12 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 168.8, 160.3, 148.0, 133.5, 128.8, 128.4, 124.6, 123.7, 122.3, 122.2, 119.2, 118.7, 110.4, 107.2, 55.8, 25.3; Anal. Calcd for C₁₆H₁₄ClN₃O₂: C, 60.86; H, 4.47; N, 13.31%; Found: C, 61.04; H, 4.49; N, 13.25%.




N-(2-(2H-Indazol-2-yl)-5-methylphenyl)benzamide (3bb): White solid (90%, 58.9 mg); R_f = 0.5 (PE:EA = 81:19); M.p. 178-179 °C; ¹H NMR (400 MHz, CDCl₃): δ 11.96 (s, 1H), 8.65 (s, 1H), 8.31 (s, 1H), 8.01-7.98 (m, 2H), 7.81-7.72 (m, 2H), 7.54-7.45 (m, 3H), 7.43-7.38 (m, 2H), 7.18-7.14 (m, 1H), 7.04-7.01 (m, 1H), 2.46 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃): δ 165.4, 149.6, 139.7, 134.9, 132.1, 131.9, 128.7, 127.7, 127.4, 126.9, 124.9, 124.1, 123.2, 122.9, 122.8, 121.9, 120.7, 116.9, 21.7; Anal. Calcd for C₂₁H₁₇N₃O: C, 77.04; H, 5.23; N, 12.84%; Found: C, 77.17; H, 5.28; N, 12.75%.




N-(2-(5-Chloro-2H-indazol-2-yl)-5-methylphenyl)benzamide (3ob): White solid (80%, 57.7 mg); $R_f = 0.55$ (PE:EA = 82:18); M.p. 184-185 °C; ^1H NMR (400 MHz, CDCl_3): δ 11.67 (s, 1H), 8.61 (s, 1H), 8.25 (s, 1H), 7.95-7.93 (m, 2H), 7.73-7.70 (m, 2H), 7.53-7.45 (m, 3H), 7.40 (d, $J = 8.0$ Hz, 1H), 7.33 (dd, $J = 9.6$ Hz, 2.0 Hz, 1H), 7.04 (d, $J = 8.4$ Hz, 1H), 2.47 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.4, 147.9, 140.0, 134.8, 132.0, 129.2, 128.8, 128.6, 127.3, 126.7, 125.0, 123.7, 123.4, 123.0, 122.3, 120.8, 119.3, 118.4, 21.7; Anal. Calcd for $\text{C}_{21}\text{H}_{16}\text{ClN}_3\text{O}$: C, 69.71; H, 4.46; N, 11.61%; Found: C, 69.87; H, 4.42; N, 11.67%.




N-(2-(2H-Indazol-2-yl)-5-methylphenyl)-4-methoxybenzamide (3bc): White solid (75%, 53.6 mg); $R_f = 0.50$ (PE:EA = 83:17); M.p. 188-189 °C; ^1H NMR (400 MHz, CDCl_3): δ 11.76 (s, 1H), 8.61 (s, 1H), 8.32 (s, 1H), 7.96-7.92 (m, 2H), 7.80 (d, $J = 8.8$ Hz, 1H), 7.76 (d, $J = 8.4$ Hz, 1H), 7.44-7.39 (m, 2H), 7.17 (t, $J = 8.0$ Hz, 1H), 7.04 (d, $J = 8.4$ Hz, 1H), 6.97-6.94 (m, 2H), 3.86 (m, 3H), 2.47 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 165.0, 162.6, 149.6, 139.7, 132.3, 129.3, 127.7, 127.2, 126.9, 124.6, 124.1, 123.2, 123.0, 122.8, 121.9, 120.7, 116.9, 113.9, 55.5, 21.7; Anal. Calcd for $\text{C}_{22}\text{H}_{19}\text{N}_3\text{O}_2$: C, 73.93; H, 5.36; N, 11.76%; Found: C, 73.75; H, 5.33; N, 11.81%.




N-(2-(2H-Indazol-2-yl)-5-methylphenyl)-4-fluorobenzamide (3bd): White solid (84%, 58.0 mg); $R_f = 0.55$ (PE:EA = 85:15); M.p. 189-190 °C; ^1H NMR (400 MHz, CDCl_3): δ 11.94 (s, 1H), 8.60 (s, 1H), 8.32 (s, 1H), 8.00-7.96 (m, 2H), 7.75 (d, $J = 9.6$ Hz, 2H), 7.44-7.39 (m, 2H), 7.19-7.12 (m, 3H), 7.05-7.03 (m, 1H), 2.46 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 166.3, 164.0 (d, $J_{\text{C}-\text{F}} = 48.0$ Hz), 149.5, 139.6, 131.9, 131.1, 129.8, 129.7, 127.9, 126.8, 124.9, 124.1, 123.1, 122.8 (d, $J_{\text{C}-\text{F}} = 7.0$ Hz), 121.9, 120.7, 116.7, 115.7 (d, $J_{\text{C}-\text{F}} = 22.0$ Hz), 21.6; Anal. Calcd for $\text{C}_{21}\text{H}_{16}\text{FN}_3\text{O}$: C, 73.03; H, 4.67; N, 12.17%; Found: C, 72.81; H, 4.72; N, 12.25%.




N-(2-(2H-Indazol-2-yl)-5-methylphenyl)-3-bromobenzamide (3be): White solid (88%, 71.5 mg); $R_f = 0.5$ (PE:EA = 83:17); M.p. 193-194 °C; ^1H NMR (400 MHz, CDCl_3): δ 12.17 (s, 1H), 8.62 (s, 1H), 8.33 (s, 1H), 8.17-8.16 (m, 1H), 7.95-7.88 (m, 2H), 7.74 (d, $J = 8.4$ Hz, 1H), 7.65-7.63 (m, 1H), 7.45-7.40 (m, 2H), 7.35 (t, $J = 8.0$ Hz, 1H), 7.19-7.15 (m, 1H), 7.05-7.03 (m, 1H), 2.46 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 163.6, 149.5, 139.6, 136.8, 134.8, 131.7, 130.3, 127.8, 126.7, 126.3, 125.0, 124.0, 123.0, 122.99, 122.91, 122.8, 122.6, 121.8, 120.6, 117.1, 21.6; Anal. Calcd for $\text{C}_{21}\text{H}_{16}\text{BrN}_3\text{O}$: C, 62.08; H, 3.97; N, 10.34%; Found: C, 62.22; H, 4.04; N, 10.25%.



N-(2-(2H-Indazol-2-yl)-5-methylphenyl)-3-(trifluoromethyl)benzamide (3bf): White solid (72%, 56.9 mg); $R_f = 0.55$ (PE:EA = 90:10); M.p. 172-173 °C; ^1H NMR (400 MHz, CDCl_3): δ 12.19 (s, 1H), 8.63 (s, 1H), 8.36 (s, 1H), 8.27 (s, 1H), 8.21 (d, $J = 7.6$ Hz, 1H), 7.81-7.74 (m, 3H), 7.62 (t, $J = 8.0$ Hz, 1H), 7.47-7.40 (m, 2H), 7.21-7.16 (m, 1H), 7.08 (d, $J = 8.4$ Hz, 1H), 2.48 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 163.7, 149.7, 139.7, 135.7, 131.5 (d, $J_{\text{C}-\text{F}} = 24.0$ Hz), 131.1, 129.7, 128.5 (q, $J_{\text{C}-\text{F}} = 4.0$ Hz), 127.9, 126.9, 125.3, 124.1, 123.2, 123.0, 122.8, 122.5, 122.0 (q, $J_{\text{C}-\text{F}} = 270.0$ Hz), 121.9, 121.2, 120.6, 116.9; Anal. Calcd for $\text{C}_{22}\text{H}_{16}\text{F}_3\text{N}_3\text{O}$: C, 66.83; H, 4.08; N, 10.63%; Found: C, 66.98; H, 4.12; N, 10.56%.




N-(2-(2H-Indazol-2-yl)-5-methylphenyl)furan-2-carboxamide (3bg): White solid (86%, 54.5 mg); $R_f = 0.45$ (PE:EA = 80:20); M.p. 140-141 °C; ^1H NMR (400 MHz, CDCl_3): δ 11.74 (s, 1H), 8.55 (s, 1H), 8.30 (s, 1H), 7.84 (d, $J = 8.8$ Hz, 1H), 7.75 (d, $J = 8.4$ Hz, 1H), 7.50 (s, 1H), 7.43-7.38 (m, 2H), 7.19-7.15 (m, 2H), 7.06-7.04 (m, 1H), 6.50 (q, $J = 2.0$ Hz, 1H), 2.46 (s, 3H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 156.8, 149.7, 148.3, 144.6, 139.7, 131.7, 127.5, 127.1, 124.9, 123.9, 123.29, 123.22, 122.8, 122.0, 120.6, 117.3, 114.9, 112.3, 21.6; Anal. Calcd for $\text{C}_{19}\text{H}_{15}\text{N}_3\text{O}_2$: C, 71.91; H, 4.76; N, 13.24%; Found: C, 71.78; H, 4.73; N, 13.35%.



N-(2-(2H-Indazol-2-yl)-5-methylphenyl)cyclohexanecarboxamide (3bh): White solid (87%, 58.0 mg); $R_f = 0.5$ (PE:EA = 85:15); M.p. 187-188 °C; ^1H NMR (400 MHz, CDCl_3): δ 10.71 (s, 1H), 8.42 (s, 1H),

8.26 (s, 1H), 7.76 (d, J = 9.2 Hz, 2H), 7.41-7.35 (m, 2H), 7.19-7.15 (m, 1H), 7.01-6.99 (m, 1H), 2.42 (s, 3H), 2.25-2.17 (m, 1H), 1.93 (d, J = 12.8 Hz, 2H), 1.79-1.75 (m, 2H), 1.50-1.41 (m, 2H), 1.32-1.21 (m, 4H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 174.9, 149.6, 139.6, 132.2, 127.5, 127.0, 124.6, 124.1, 123.4, 123.2, 122.7, 121.9, 120.6, 117.1, 46.8, 29.6, 25.9, 25.8, 21.6; Anal. Calcd for $\text{C}_{21}\text{H}_{23}\text{N}_3\text{O}$: C, 75.65; H, 6.95; N, 12.60%; Found: C, 75.45; H, 6.91; N, 12.54%.



4-Chloro-2-(5-fluoro-2H-indazol-2-yl)aniline (4na): White solid (89%, 46.5 mg); R_f = 0.55 (PE:EA = 90:10); M.p. 218-219 °C; ^1H NMR (400 MHz, CDCl_3): δ 8.15 (s, 1H), 7.71 (q, J = 4.8 Hz, 1H), 7.33-7.27 (m, 2H), 7.18-7.12 (m, 2H), 6.79 (d, J = 8.8 Hz, 1H), 4.93 (s, 2H); $^{13}\text{C}\{\text{H}\}$ NMR (100 MHz, CDCl_3): δ 158.8 (d, $J_{\text{C}-\text{F}} = 239.0$ Hz), 147.0, 140.0, 129.4, 126.6, 124.5, 123.7 (d, $J_{\text{C}-\text{F}} = 8.0$ Hz), 122.4, 121.2 (d, $J_{\text{C}-\text{F}} = 12.0$ Hz), 119.7 (d, $J_{\text{C}-\text{F}} = 9.0$ Hz), 118.9, 118.6 (d, $J_{\text{C}-\text{F}} = 7.0$ Hz), 102.8 (d, $J_{\text{C}-\text{F}} = 24.0$ Hz); Anal. Calcd for $\text{C}_{13}\text{H}_9\text{ClFN}_3$: C, 59.67; H, 3.47; N, 16.06%; Found: C, 59.55; H, 3.54; N, 16.16%.



4. References:

1. M. R. Kumar, A. Park, N. Park and S. Lee, *Org. Lett.*, 2011, **13**, 3542–3545.
2. S. Samanta, S. Mondal, D. Ghosh and A. Hajra, *Org. Lett.*, 2019, **21**, 4905-4909.
3. (a) U. Dutta, S. Maiti, S. Pimparkar, S. Maiti, L. R. Gahan, E. H. Krenske, D. W. Lupton and D. Maiti, *Chem. Sci.*, 2019, **10**, 7426-7432; (b) A. Modi, P. Sau, N. Chakraborty and B. K. Patel, *Adv. Synth. Catal.*, 2019, **361**, 1368-1375.

5. NMR spectra for the synthesized products

8.376
 7.803
 7.802
 7.781
 7.717
 7.636
 7.337
 7.322
 7.301
 7.299
 7.259
 7.130
 7.113
 7.110
 7.092

— 2.428 —




Current Data Parameters
 NAME Dr. A HAJRA 2020 1H
 EXPNO 34
 PROCNO 1

F2 - Acquisition Parameters
 Date 20200116
 Time 12.14
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 TD 32768
 SOLVENT CDCl₃
 NS 8
 DS 2
 SWH 8223.685 Hz
 FIDRES 0.250967 Hz
 AQ 1.9922944 sec
 RG 135.7
 DW 60.800 usec
 DE 6.50 usec
 TE 295.7 K
 D1 1.00000000 sec
 TDO 1

===== CHANNEL f1 ======
 SFO1 400.1524711 MHz
 NUC1 1H
 P1 14.75 usec
 PLW1 12.00000000 W

F2 - Processing parameters
 SI 16384
 SF 400.1500091 MHz
 WDW EM
 SSB 0
 LB 0.30 Hz
 GB 0
 PC 1.00






BRUKER


Current Data Parameters
 NAME Dr. A HAJRA 2020 1H
 EXPNO 38
 PROCNO 1

F2 - Acquisition Parameters
 Date_ 20200116
 Time_ 20.46
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zg30
 TD 32768
 SOLVENT CDCl3
 NS 8
 DS 2
 SWH 8223.685 Hz
 FIDRES 0.250967 Hz
 AQ 1.9922944 sec
 RG 67.81
 DW 60.800 usec
 DE 6.50 usec
 TE 295.1 K
 D1 1.0000000 sec
 TDO 1

===== CHANNEL f1 =====
 SF01 400.1524711 MHz
 NUC1 1H
 P1 14.75 usec
 PLW1 12.00000000 W

F2 - Processing parameters
 SI 16384
 SF 400.1500090 MHz
 WDW EM
 SSB 0 0.30 Hz
 LB 0
 GB 1.00
 PC





BRUKER


Current Data Parameters
 NAME Dr. A HAJRA-2019-13C
 EXPNO 488
 PROCN0 1


F2 - Acquisition Parameters
 Date 20191101
 Time 13.03
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 T1 32768
 SOLVENT CDCl3
 NS 156
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 87.66
 DW 20,800 usec
 DE 6.50 usec
 TE 298.3 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1


===== CHANNEL f1 =====
 SFO1 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.00000000 W


===== CHANNEL f2 =====
 SFO2 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177874 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40









Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPNO 306
PROCNO 1

```

F2 - Acquisition Parameters
Date_      20190804
Time_      18.32
INSTRUM_   spect
PROBHD_    5 mm FABBO BB/
PULPROG_  zgpp30
TD_        32768
SOLVENT_   CDC13
NS_        220
DS_        2
SWH_       24038.461 Hz
FIDRES_   0.733596 Hz
AQ_        0.6815744 sec
RG_        106.66
DW_        20.800 usec
DE_        6.50 usec
TE_        299.1 K
D1_        2.0000000 sec
D11_       0.03000000 sec
TD0_       1

```


```
===== CHANNEL f1 =====
SFO1      100.6278588 MHz
NUC1          13C
P1            8.90 usec
PLW1      54.00000000 W
```


```
===== CHANNEL f2 =====
SFO2          400.1516006 MHz
NUC2           1H
CPDPRG[2      waltz16
PCPD2         90.00 usec
PLW2          12.0000000 W
PLW12         0.32231000 W
PLW13         0.16212000 W
```


```


F2 - Processing parameters
SI           16384
SF          100.6177874 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40


```















BRUKER



Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPN0 275
PROCNO 1

```

F2 - Acquisition Parameters
Date          20190623
Time          11.55
INSTRUM      spect
PROBHD      5 mm PABBO BB/
PULPROG     zgpg30
TD            32768
SOLVENT       CDCl3
NS             512
DS              2
SWH         24038.461 Hz
FIDRES     0.733596 Hz
AQ        0.6815744 sec
RG           186.42
DW           20.800 used
DE            6.50 used
TE            303.6 K
D1    2.00000000 sec
D11       0.03000000 sec
TDO          1

```


===== CHANNEL f1 =====
SFO1 100.6278588 MHz
NUC1 13C
P1 8.90 used
PLW1 54.0000000 w



```
===== CHANNEL f2 =====
SFO2          400.1516006 MHz
NUC2           1H
CPDPRG[2]      waltz16
PCPD2          90.00 used
PLW2           12.0000000 W
PLW12          0.32231000 W
PLW13          0.16212000 W
```

```

F2 - Processing parameters
SI           16384
SF          100.6177844 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40

```





Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPNO 303
PROCNO 1

```

F2 - Acquisition Parameters
Date_      20190803
Time_      18.14
INSTRUM   spect
PROBHD   5 mm PABBO BB/
PULPROG zgpp30
TD        32768
SOLVENT   CDC13
NS         470
DS          2
SWH       24038.461 Hz
FIDRES   0.733596 Hz
AQ        0.6815744 sec
RG        106.66
DW        20.800 usec
DE        6.50 usec
TE        299.0 K
D1        2.0000000 sec
D11       0.03000000 sec
TD0           1

```

----- CHANNEL f1 -----
SFO1 100.6278588 MHz
NUC1 13C
P1 8.90 usec
FLW1 54.00000000 W

```


===== CHANNEL f2 =====
SFO2          400.1516006 MHz
NUC2           1H
CPDPRG[2]     waltz16
PCPD2          90.00 usec
PLW2          12.0000000 W
PLW12         0.32231000 W
PLW13         0.16212000 W


```

```

F2 - Processing parameters
SI           16384
SF          100.6177858 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40

```





BRUKER


Current Data Parameters
 NAME Dr. A HAJRA-2019-13C
 EXPNO 346
 PROCNO 1


F2 - Acquisition Parameters
 Date 20190828
 Time 20.27
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 250
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 62.69
 DW 20.800 usec
 DE 6.50 usec
 TE 298.3 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1

===== CHANNEL f1 =====
 SF01 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.00000000 W

===== CHANNEL f2 =====
 SF02 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177889 MHz
 WDW EM
 SSB 0 1.00 Hz
 LB 0
 GB 0 1.40
 PC





BRUKER


Current Data Parameters
 NAME Dr. A HAJRA-2020-13C
 EXPNO 30
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 20200119
 Time 19.56
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 250
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 186.42
 DW 20.800 usec
 DE 6.50 usec
 TE 296.1 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1


===== CHANNEL f1 =====
 SF01 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.0000000 W


===== CHANNEL f2 =====
 SF02 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177857 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40












¹H of VBpg 255 8





Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPNO 314
PROCNO 1

```

F2 - Acquisition Parameters
Date_      20190809
Time_      12.14
INSTRUM_   spect
PROBHD_   5 mm PABBO BB/
PULPROG_ zpgg30
TD_        32768
SOLVENT_  CDCl3
NS_        460
DS_        2
SWH_       24038.461 Hz
FIDRES_  0.733596 Hz
AQ_        0.6815744 sec
RG_        106.66
DW_        20.800 usec
DE_        6.50 usec
TE_        302.2 K
D1_        2.00000000 sec
D11_       0.03000000 sec
TDO_       1

```

```
===== CHANNEL f1 =====
SFO1      100.6278588 MHz
NUC1      13C
P1        8.90  usec
PLW1      54.00000000 W
```

```
===== CHANNEL f2 ======  
SFO2          400.1516006 MHz  
NUC2           1H  
CPDPRG[2]      waltz16  
PCPD2         90.00 usec  
PLW2          12.0000000 W  
PLW12         0.32231000 W  
PLW13         0.16212000 W
```

```

F2 - Processing parameters
SI          16384
SF          100.6177842 MHz
WDW          EM
SSB          0
LB          1.00 Hz
GB          0
PC          1.40

```



1H of VBPG 255/10


— 10.515


8.209
8.057
7.653
7.630
7.329
7.308
7.260
7.093
7.087
7.069
7.064
6.923
6.714
6.691
6.689


3.861
3.852


— 2.114














BRUKER


Current Data Parameters
 NAME Dr. A HAJRA-2019-13C
 EXPNO 354
 PROCNO 1


F2 - Acquisition Parameters
 Date_ 2019099
 Time_ 9.25
 INSTRUM spect
 PROBHD 5 mm PABBO BB/
 PULPROG zgpg30
 TD 32768
 SOLVENT CDCl3
 NS 256
 DS 2
 SWH 24038.461 Hz
 FIDRES 0.733596 Hz
 AQ 0.6815744 sec
 RG 186.42
 DW 20.800 usec
 DE 6.50 usec
 TE 298.5 K
 D1 2.0000000 sec
 D11 0.03000000 sec
 TDO 1


===== CHANNEL f1 ======
 SF01 100.6278588 MHz
 NUC1 13C
 P1 8.90 usec
 PLW1 54.00000000 W



===== CHANNEL f2 ======
 SF02 400.1516006 MHz
 NUC2 1H
 CPDPRG[2] waltz16
 PCPD2 90.00 usec
 PLW2 12.00000000 W
 PLW12 0.32231000 W
 PLW13 0.16212000 W

F2 - Processing parameters
 SI 16384
 SF 100.6177886 MHz
 WDW EM
 SSB 0
 LB 1.00 Hz
 GB 0
 PC 1.40









Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPNO 355
PROCNO 1

```

F2 - Acquisition Parameters
Date_           20190909
Time            9.07
INSTRUM         spect
PROBHD         5 mm PABBO BB/
PULPROG        zpgp30
TD              32768
SOLVENT         CDCl3
NS              256
DS              2
SWH             24038.461 Hz
FIDRES         0.733596 Hz
AQ              0.6815744 sec
RG              120.16
DW              20.800 usec
DE              6.50
TE              298.5 K
D1              2.0000000 sec
D11             0.03000000 sec
TDO              1

```

----- CHANNEL f1 -----
SFO1 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.0000000 W

```
===== CHANNEL f2 =====
SFO2          400.1516006 MHz
NUC2           1H
CPDPRG[2      waltz16
PCPD2          90.00 usec
PLW2          12.0000000 W
PLW12         0.32231000 W
PLW13         0.16212000 W
```

```



F2 - Processing parameters
SI           16384
SF          100.6177854 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40


```


— 11.961


8.657
8.311
8.017
8.008
8.005
7.997
7.992
7.987
7.810
7.808
7.787
7.750
7.729
7.546
7.543
7.536
7.527
7.521
7.514
7.510
7.497
7.483
7.479
7.466
7.462
7.457
7.431
7.410
7.404
7.390
7.387
7.259
7.184
7.168
7.165
7.163
7.147
7.042
7.040
7.022
7.018


— 2.466















Current Data Parameters
NAME Dr. A HAJRA-2020-13C
EXPNO 27
PROCNO 1

```

F2 - Acquisition Parameters
Date_           20200119
Time            11.21
INSTRUM         spect
PROBHD         5 mm PABBO BB/
PULPROG        zgppg30
TD              32768
SOLVENT         CDCl3
NS              300
DS              2
SWH             24038.461 Hz
FIDRES         0.733596 Hz
AQ              0.6815744 sec
RG              120.16
DW              20.800 usec
DE              6.50 usec
TE              296.3 K
D1              2.00000000 sec
D11             0.03000000 sec
TDO              1

```

===== CHANNEL f1 =====
SFO1 100.6278588 MHz
NUC1 13C
P1 8.90 usec
PLW1 54.00000000 W

```


===== CHANNEL f2 =====
SFO2          400.1516006 MHz
NUC2           1H
CPDPRG[2      waltz16
PCPD2         90.00 usec
PLW2          12.00000000 W
PLW12         0.32321000 W
PLW13         0.16212000 W

```


```


F2 - Processing parameters
SI           16384
SF          100.6177859 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40



```



BRUKER







Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPNO 364
PROCNO 1

```

- Acquisition Parameters
e_                               20190912
e_                               18.49
TRUM                            spect
BHD    5 mm PABBO BB/
PROG   zgpp30
                  32768
VENT    CDC13
                  200
                  2
RES    24038.461 Hz
      0.733596 Hz
      0.6815744 sec
      62.69
      20.800 usec
      6.50  usec
      298.8 K
      2.0000000 sec
      0.03000000 sec
)
                                         1

```

```
===== CHANNEL f1 =====
SFO1      100.6278588 MHz
NUC1      13C
P1        8.90 usec
PLW1      54.0000000 W
```

```
===== CHANNEL f2 =====
SF02          400.1516006 MHz
NUC2           1H
CPDPRG[2      waltz16
PCFD2         90.00 usec
PLW2          12.00000000 W
PLW12         0.32231000 W
PLW13         0.16212000 W
```

```



F2 - Processing parameters
SI           16384
SF          100.6177888 MHz
WDW          EM
SSB          0
LB           1.00 Hz
GB          0
PC          1.40


```


— 12.192


8.638
8.360
8.270
8.227
8.208
8.205
8.194
8.184
8.164
8.144
8.124
8.104
8.084
8.064
8.044
8.024
8.004
7.984
7.964
7.944
7.924
7.904
7.884
7.864
7.844
7.824
7.804
7.784
7.764
7.744
7.724
7.704
7.684
7.664
7.644
7.624
7.604
7.584
7.479
7.458
7.444
7.443
7.426
7.406
7.404
7.259
7.210
7.202
7.184
7.182
7.164
7.099
7.078


— 2.488













Current Data Parameters
NAME Dr. A HAJRA-2019-13C
EXPNO 363
PROCNO 1

F2 - Acquisition Parameters
Date_ 20190912
Time 8.07
INSTRUM spect
PROBHD 5 mm PABBO BB/
PULPROG zpg30
TD 32768
SOLVENT CDCl3
NS 256
DS 2
SWH 24038.461 Hz
FIDRES 0.73359 Hz
AQ 0.6815744 sec
RG 135.7
DW 20.800 usec
DE 6.50 usec
TE 299.3 K
D1 2.0000000 sec
D11 0.0300000 sec
TDO 1

===== CHANNEL f1 =====
SF01 100.6278588 MHz
NUC1 13C
PI 8.90 usec
PLW1 54.0000000 W

===== CHANNEL f2 =====
SF02 400.1516006 MHz
NUC2 1H
CPDPFG[2 waltz16
PCPD2 90.00 usec
PLW2 12.0000000 W
PLW12 0.32231000 W
PLW13 0.16212000 W

F2 - Processing parameters
SI 16384
SF 100.6177842 MHz
WDW EM
SSB 0
LB 1.00 Hz
GB 0
PC 1.40

